Please login to the form below

What do NHS changes and the Life Sciences Vision mean for medicines?

With the publication of the new Life Sciences Vision, a new NHS Bill, and new Health Secretary and NHS England Chief Executive, there are many fresh additions to add to the blur of change in the NHS. But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the NHS, one which articulates their contribution to the prevention agenda and how they can relieve the burden of care on the health system.

With the publication of a new Life Sciences Vision (LSV), the first major piece of health legislation in nine years and a new Health Secretary and NHS England Chief Executive, there are many fresh additions to the blur of change in the NHS. But what do they mean for medicines and industry’s value story?

The launch of a new life sciences strategy is an important and positive step for industry. It sets out a cross-government approach to achieving the ambition of making the UK a life sciences superpower. In contrast to the 2017 Life Sciences Industrial Strategy, the LSV is a Government publication endorsed by the Department of Health and Social Care (DHSC) and NHS England - the LSIS was a series of industry recommendations to the Government. The LSV also clearly states the ambition to “make the NHS the country’s most powerful driver of innovation – through the development, testing and adoption of new technologies at a population scale.”

The LSV does not sit in isolation, it is a key part of the Government’s economic recovery strategy and is closely tied to the Plan for Growth and forthcoming Innovation Strategy. It also rightly supports the Government’s ambitions in health by identifying the role of life sciences in addressing seven ‘great health challenges’ for the UK population.

These seven challenges (or ‘’silent pandemics’ as the LSV calls them) are neurodegeneration; early diagnosis and treatment in cancer, including immune therapies; vaccine development and manufacturing; cardiovascular disease and obesity; respiratory disease; the underlying biology of ageing; and mental health. Also threaded through the strategy is the drive to increase research in the NHS and the harnessing of genomic and health data for this purpose.

All this is very positive. But there is always a question when reviewing new strategies – how much of it will be implemented?

Previous strategies show that whilst the Government has been able to make changes to the research and skills environment, progress on the adoption of medicines in the NHS has been slower. A government review in 2005 noted the low and slow use of medicines in the NHS, and half a dozen life science strategies later, the problem is still to be fixed.

The NHS rightly focused on pandemic recovery and record waiting lists. Companies need to clearly articulate how therapies relieve the burden on the NHS, particularly hospital-based care.

An NHS rightly focused on pandemic recovery, record waiting lists and implementing new structural changes will need strong incentives and direction from DHSC if the NHS elements of LSV are to be achieved. Ahead of the next election, DHSC Ministers will share the NHS’s focus if the Government is to avoid the potential political backlash from up to 1 in 4 adults in England waiting for NHS treatment.

Ministers will need to set clear goals for the NHS’s implementation of the LSV. And a cross Government effort to retain the connected health and economic benefits of the LSV will be needed to ensure DHSC and NHS accountability.

For industry, there is also a role to play, and companies should consider how their value story may need to evolve.

The LSV restates the NHS Long Term Plan’s narrative of the need for prevention, population health and better management of chronic conditions, for the benefit of patients but also the sustainability of the NHS. Companies have a major role to play in this need to clearly articulate their role.

Rare disease, advanced and specialist therapies have sometimes been seen as a burden for payers focused on other bigger priorities for larger patient populations. Meanwhile, the value story from industry has often led with the patient benefit addressing unmet need. Patient benefit is of course crucial, but therapies need to more clearly and prominently explain how they relieve the patient burden on the NHS, particularly on hospital-based care. Now is the time to show how these innovations can free up vital space in acute care by preventing or reducing the number of planned or unplanned patient visits to hospital and demands on staff time.

During the pandemic we saw how local NHS clinicians were quick to adopt and switch to treatments that reduced pressure on the NHS, reworking formularies and choosing newer and sometimes more expensive treatment (even going outside of NICE guidance) because of this prioritised aspect of product value. One senior NHS hospital manager told me recently, “if a treatment can help with recovery of elective care, then you have my attention.”

Industry must maintain its advocacy with the new leaders at the top of the NHS and Government to ensure clear incentives are in place to drive the LSV. But it is also up to every company and every brand to communicate their value story more clearly to a health service under incredible pressure. To be successful in this new world, industry must be the partner of choice it always aspires to be.

20th September 2021

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

Will the NHS be safe in Liz Truss’s Hands?
As expected, Liz Truss has been anointed as the new Prime Minister. One of her major challenges is the NHS and, with only two years to another general election, she does not have much time to restore falling public confidence in the service.
Hanover Communications
A new prescription for the U.S. healthcare market?
Last month the U.S. Government passed the Inflation Reduction Act, paving the way for unprecedented drug pricing reforms across the country. In a market with spiralling healthcare costs, and increasing stories of patients missing out, or rationing treatment, the Act is welcomed by many. But it’s also severely criticised by others, including representatives from the pharmaceutical industry who say it jeopardises future innovation and drug discovery. As the largest pharmaceuticals market, the impact of the legislation will be felt outside of the U.S., but what does this look like, in the short and long-term? Is it a proverbial drop in the ocean, or is a storm brewing?
Hanover Communications
What's next for the 'indispensable' health system?
No one is remotely indispensable” – those of the words many of us have heard these past few weeks. As Boris Johnson and the previously incumbent Cabinet are now considering their next moves, where does that leave health policy at one of the most volatile points in recent history? We were set for a bumper few months of hotly anticipated announcements, including the 10-Year Cancer  Plan response, the Women’s Health Strategy, and the implementation plan for the Life Sciences Vision, amongst many others. But what will happen as the forthcoming leadership contest dominates the column inches? How will the Civil Service and NHS stand up to the challenges it faces without certainty of who is steering the ship? We will explore some of the possibilities of what will happen next, and most importantly, how we in communications can support the health system at such a critical time post-pandemic. To find out, read the latest blog on the PM Hub, penned by Hanover Health's Senior Account Director Ursula Ritz.
Hanover Communications
How can the UK be a catalyst for change in women’s health? 
Women’s health has once again been thrust to the fore, with almost daily stories on hormone replacement therapy (HRT) supply shortages in the UK providing us with a stark reminder of the challenges women are facing in this country every day. The good news is, the UK Government is making a genuine and concerted effort to tackle women’s health issues, having set out its Vision for women’s health in December, and a full Strategy due to be published imminently. We have a real opportunity to change women’s experience of healthcare for the better, but we cannot afford to get this wrong. In her latest blog, Hanover’s Georgia Hunt explores how the upcoming Women’s Health Strategy should address the concerns of women today and improve the lives of the women of tomorrow.
Hanover Communications
Innovative contracting at the top of the market access agenda
Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.
Hanover Communications
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.
Hanover Communications